Investor Presentaiton
API Business
Global Market Size: Synthetic API
CAGR (2018-22): 6.7%
149
123
131
129
Industry
Overview
➤ 53% of outsourced API market is generics (1)
Global Synthetic API market is US$115bn in 2018 and is expected to grow at a
CAGR of 6.7% from 2018 to 2022F to reach US$149bn (1)
115
62
(US$bn)
48
51
53
46
67
72
78
83
87
2018E
2019F
2020F
2021F
2022F
■Captive
Outsourced
Business
Overview
One of the global suppliers with market leadership in select key API products (1)
~80% of commercialized portfolio is in lifestyle driven therapeutic areas such as CVS, CNS, anti-infective and non-communicable diseases
~60% of API sales are to regulated markets
Sartans continue to be a key focus area
API facility at Nanjangud, Karnataka (USFDA, PMDA Japan, KFDA Korea, COFEPRIS Mexico and Brazil ANVISA certifications) (2)
Product
Risperidone
Products (1)
Oxcarbazepine
Jubilant Global Market Share(1)
c.33%
c.30%
Carbamazepine
Pinaverium
20%
20%
Continue to be a preferred supplier to our customers
Product
Meclizine
Citalopram
Donepezil
Jubilant Global Market Share(1)
20%
18%
16%
Strategy
Focus on product selection, new product launches and increasing market share of existing products
Well differentiated strategy of products and markets, focus on cost optimization supported by highly capable team with a proven track record to drive
sustainable growth
Increasing the range of products in key markets such as US, Europe and expanding our geographical reach in select Emerging Markets
Continue to invest in R&D to build-up product pipeline and capacity expansion at plants
(1)
Source: Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic
Pharmaceutical Industry
JUBILANT
LIFESCIENCESView entire presentation